Lauren Carrico, APRN
Family · Elizabethtown, KYNPI 1851899793
Payments from drug & device makers
Across 101 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$508
- Medtronic$215
- Coloplast$213
- Astellas Pharma US Inc$176
- Ferring Pharmaceuticals Inc.$150
- AbbVie$130
- plus $910 from 29 others
What the payments were for
- Speaking & faculty fees$311%
- Food & beverage$2,12092%
- Education$1527%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 28 | $508 |
| Medtronic | 8 | $215 |
| Coloplast | 3 | $213 |
| Astellas Pharma US Inc | 7 | $176 |
| Ferring Pharmaceuticals Inc. | 1 | $150 |
| AbbVie | 7 | $130 |
| 180 Medical, Inc. | 3 | $87 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $67 |
| Vertex | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Braintree Laboratories, Inc. | 3 | $50 |
| Johnson & Johnson | 3 | $48 |
| Accord Healthcare, Inc. | 2 | $42 |
| Olympus America Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Calyxo, Inc. | 2 | $35 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| Pacira Pharmaceuticals Incorporated | 2 | $29 |
| Axonics, Inc. | 2 | $28 |
| Urovant Sciences Inc | 2 | $28 |
| Dentsply IH AB | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| AstraZeneca | 1 | $21 |
| Organogenesis Inc. | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $19 |
| Urogen Pharma, Inc. | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Convatec Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Teleflex LLC | 1 | $16 |
| Ambu Inc. | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
| Polynovo North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Luja Coude$184
- ADSTILADRIN$150
How this compares
$2,303 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 230 | $199,767 |
| MyrbetriqMirabegron | 126 | $116,482 |
| Tamsulosin Hcl | 851 | $12,051 |
| Estradiol | 172 | $7,303 |
| Finasteride | 528 | $6,626 |
| Oxybutynin Chloride ErOxybutynin Chloride | 45 | $1,704 |
| Potassium Citrate ErPotassium Citrate | 12 | $1,698 |
| NitrofurantoinNitrofurantoin Macrocrystal | 37 | $1,243 |
| Solifenacin Succinate | 17 | $928 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 71 | $812 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 34 | $727 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 33 | $674 |
| Doxazosin Mesylate | 47 | $668 |
| Metronidazole | 21 | $586 |
| Doxycycline Hyclate | 41 | $489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $508 | $199,767230 claims |
| Astellas Pharma US IncMyrbetriq | $176 | $116,482126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.
Other family in Elizabethtown
- Ashley SnellenElizabethtown$190K
- Gwendolynn ThomasElizabethtown$12K
- Bonnie HillLouisa$372K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.